Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
5 Results for "
Menin-MLL1
" in MedChemExpress (MCE) Product Catalog:
Products (5)
5 Results for "Menin-MLL1" in MCE Product Catalog:
3
3 Cited Publications
Target:
Research Areas:
MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC50 of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis [1].
Cat. No.: HY-172416
CAS No.: 2939850-17-4
Synonyms: ZE63-0302
Target:
Research Areas:
Balomenib (ZE63-0302) is an orally bioavailable menin-KMT2A interaction inhibitor. Balomenib disrupts menin-KMT2A binding, reverses aberrant HOX gene expression. Balomenib inhibits Meis1 mRNA expression in KMT2A-rearranged acute myeloid leukemia cells. Balomenib can be used for the research of leukemia [1].
Cat. No.: HY-117948
CAS No.: 1560968-49-1
Research Areas:
ML399 is a Menin-MLL1 protein-protein interaction inhibitor with an IC50 of 90 nM. ML399 inhibits the proliferation of transformed mouse bone marrow cells. ML399 binds to the hERG potassium channel, exhibits superior in vitro physicochemical, drug metabolism and pharmacokinetic (DMPK) parameters, and has an extended half-life in rodents. ML399 can be used for research on acute myeloid leukemia and acute lymphoblastic leukemia [1].
Cat. No.: HY-117365
CAS No.: 1887178-64-4
Target:
Research Areas:
MI-1481 is a highly potent inhibitor of the Menin-MLL1 interaction with IC50 of 3.6 nM. MI-1481 markedly reduces cell growth of murine bone marrow cells transformed and inhibits leukemia progression [1].
Cat. No.: HY-114162B
CAS No.: 2169919-27-9
Synonyms: SNDX-50469 mesylate
Target:
Research Areas:
VTP50469 mesylate is a potent, and selective Menin-MLL1 inhibitor that effectively targets MLL-rearranged and NPM1c+ leukemia. VTP50469 mesylate selectively kills cell lines with MLL rearrangements and NPM1c+ mutations. VTP50469 mesylate displaces Menin from protein complexes and inhibits MLL's chromatin occupancy at specific genes, leading to significant changes in gene expression, differentiation, and apoptosis. VTP50469 demonstrates dramatic reductions in leukemia burden in patient-derived xenograft models of MLL-r acute myeloid leukemia and MLL-r acute lymphoblastic leukemia, with some mice remaining disease-free for over a year post-treatment.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
